Says “tempering” enthusiasm, says wants to make sure that “we provide guidance that aligns to the level of transformation that is going to take place in 2026.” Comments taken from the 44th Annual J.P. Morgan Healthcare Conference.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target raised to $99 from $97 at Bernstein
- Zimmer Biomet downgraded to Sell from Neutral at Goldman Sachs
- Zimmer Biomet: Buy Rating Driven by Discounted Valuation, Lowered Expectations, and Execution Upside
- Zimmer Biomet downgraded to Market Perform from Outperform at Raymond James
- Evercore ISI upgrades four, downgrades six in MedTech and Tools